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Rapid Diagnostic Testing for Plasmodium vivax
and NonfalciparumMalaria in Endemic Areas
Yemisi Takwoingi, DVM; Katharine Abba, MSc; Paul Garner, MD
Approximately 40%of theworld's population is at risk for Plasmo-
dium vivax malaria.1 Resistance to chloroquine and other anti-
malarials is more likely for Plasmodium falciparum than other
Plasmodium species, and spe-
cies identification is important to
select appropriate treatment.
The gold standard for diagnos-
ingmalaria ismicroscopic examinationof thick and thinblood films.
However, timely, high-quality microscopy may be unavailable in
resource-poor settings. Immunochromatographic rapid diagnostic
tests (RDTs) are alternatives tomicroscopic diagnosis. Pan-specific
RDTs distinguish P falciparum (ormixed) infections from infections
with only nonfalciparumspecies; differentiationbetweennonfalci-
parumspecies (Pvivax fromPlasmodiumovaleandPlasmodiumma-
lariae) is notpossible.More recentlydeveloped, vivax-specificRDTs
can detect P vivax monoinfection or co-infection. This JAMA
Clinical Evidence Synopsis summarizes a Cochrane review2 assess-
ing the accuracy of RDTs for detecting P vivax and nonfalciparum
malaria in endemic countries.
Summary of Findings
In 8 studies of vivax-specific RDTs, involving 3682 participants of
whom 531 had vivax malaria, sensitivities ranged from 66% to
100% and specificities ranged from 98% to 100%. In pooled
analyses, compared with microscopy, vivax-specific RDTs had a
sensitivity of 95% (95% CI, 86%-99%) and specificity of 99%
(95% CI, 99%-100%) (Table). For pan-specific RDTs, the sensi-
tivities from individual studies varied from 25% to 100% and had
wide 95% CIs. Specificities varied between 89% and 100% and
had narrow CIs. Where there were sufficient data, we compared
the accuracy of commercial brands within each type of pan-
specific RDT, and there was no association of commercial brand
with superior sensitivity or specificity. The variability and uncer-
tainty in sensitivity estimates are probably due to the small num-
ber of malaria cases in some studies. The mean specificity of each
of the 3 types of pan-specific RDTs was high (Table), with approxi-
mately 1% to 2% of noncases being false-positives when com-
pared with microscopy. Conversely, mean sensitivities were low,
with false-negative rates for nonfalciparum species between
11% and 22%.
Discussion
In P vivax endemic areas, vivax-specific RDTs have higher sensitiv-
ity formalaria thanpan-specificRDTs.Pan-specificRDTsmaybeuse-
ful in areas where themajority of malaria is caused by P falciparum
or mixed infection because they are sensitive for the detection of
P falciparum.3
When we updated our search in December 2014, we found 4
additional studies that meet the review inclusion criteria. Three
of the studies, with sample sizes of 677 participants,4 1762
participants,5 and 200 participants,6 respectively, compared
vivax-specific RDTs with microscopy. Their findings were consis-
tent with those for studies included in the published review,
although Vyas et al4 found a lower specificity (90%). Inclusion of
the 3 new studies in an updated meta-analysis of vivax-specific
RDTs gave a mean sensitivity of 94% (95% CI, 86%-98%) and a
mean specificity of 99% (95% CI, 98%-100%), similar to those of
the original meta-analysis. The fourth new study by Chong et al,7
with a sample size of 185 participants assessed a type 3 pan-
specific RDT against microscopy and polymerase chain reaction
for detection of nonfalciparum malaria. The study by Chong et al
was consistent with the included studies for type 3 RDTs, and is
unlikely to change the conclusions of the review.
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CLINICAL QUESTION How sensitive and specific are rapid diagnostic tests (RDTs) for
diagnosing Plasmodium vivax and nonfalciparummalaria in endemic areas?
BOTTOM LINE Vivax-specific RDTs were highly sensitive and specific when compared with
microscopy (the gold standard) for detecting P vivaxmalaria. RDTs that can only distinguish
Plasmodium falciparum from nonfalciparummalaria were less sensitive.
Evidence Profile
No. of studies: 37 publications reporting 47 study cohorts
Study years: Conducted, 1998–2011; published, 1999–2013
Last search date:December 31, 2013
No. of participants: 22 862with symptoms suggestive of
uncomplicatedmalaria
Men: 8304 (56%) Women: 6399 (44%); only 34 studies (14 703
participants) reported sex
Race/ethnicity:Unavailable
Age range:0-94 years; 5 studies did not report age
Settings: Ambulatory health care settings in nonfalciparum
malaria endemic areas
Countries: 18 countries in Asia, Africa, and South America
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Limitations
Study quality and descriptions and reporting of patient character-
istics and reference standards were variable. Microscopy is imper-
fect, and it is possible that an RDT result may have been accurate
in some cases of discordant results between microscopy and RDT.
However, studies using polymerase chain reaction as the refer-
ence standard gave similar results to those using microscopy.
Insufficient data were available to assess the effect of parasite
density on test accuracy.
Comparison of FindingsWith Current Practice Guidelines
TheWorldHealthOrganization recommendsdiagnosisbyeithermi-
croscopy or RDT before starting antimalarial treatment.8 Local
malaria epidemiology, geography, resources, and infrastructurewill
influence the decision to usemicroscopy or an RDT.
Areas in Need of Future Study
Research evaluating clinical algorithms using vivax-specific RDTs in
endemic areas is needed.
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Table. Summary of Accuracy of Rapid Diagnostic Tests for Diagnosing Plasmodium vivax and NonfalciparumMalaria













RDTs for P vivaxMalaria (With or Without Other Plasmodium Species) Verified by Microscopy
Vivax-specific Pf HRP-2 and pLDH-Pv 8 580 3682 19 (2-45) 95 (86-99) 99 (99-100)
Pan-Specific RDTs for NonfalciparumMalaria
Verified by microscopy
Type 2 Pf HRP-2 and aldolase 11 958 6879 14 (7-32) 78 (73-82) 99 (97-99)
Type 3 Pf HRP-2 and pLDH-pan 23 1537 11234 10 (7-36) 78 (69-84) 99 (98-99)
Type 4 pLDH-Pf and pLDH-pan 10 986 3831 27 (8-33) 89 (79-95) 98 (97-99)
Verified by PCR
Type 3 Pf HRP-2 and pLDH-pan 5 300 1639 15 (7-33) 81 (72-88) 99 (97-99)
Abbreviations: HRP-2, histidine-rich protein 2; PCR, polymerase chain reaction;
Pf, Plasmodium falciparum; pLDH, plasmodium lactate dehydrogenase;
Pv, Plasmodium vivax; RDT, rapid diagnostic test.
Source: Data adapted from Abba et al, 2014,2 under the terms of the Creative
Commons Attribution Noncommercial license.
a RDTs use different types of antibody or antibody combinations to detect
Plasmodium antigens. Some antibodies aim to detect a particular species
whereas others are panmalarial aiming to detect all Plasmodium species.
Type 2 and type 3 RDTs use antibodies that detect the HRP-2 antigen
expressed only by P falciparum. Both RDTs also include pan-specific
antibodies: type 2 detects aldolase and type 4 detects pLDH from all
Plasmodium species. Type 4 RDTs use antibody combinations that detect
P falciparum specific pLDH or pLDH from any Plasmodium species. Seven
studies assessedmore than 1 RDT by giving participants all RDTs
(head-to-head comparison).
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